Core Insights - Bausch + Lomb Corporation reported record financial results for Q4 2025, with revenue increasing by 7% to $1.405 billion and adjusted EBITDA rising by 27% to $330 million, contributing to a full-year revenue of $5.101 billion driven by a diversified portfolio [1][3] Financial Performance - The pharmaceutical segment experienced a 14% growth in Q4, while the Vision Care division, bolstered by an 8% increase in contact lens sales, generated $778 million in revenue for the quarter [1] - The dry eye treatment Miebo was a standout performer, with Q4 revenue soaring by 111% to $112 million, attributed to marketing investments and a strong sales force [2] - The surgical segment achieved a 20% growth in premium intraocular lenses, recovering from a previous product recall [2] Future Outlook - For 2026, the company aims to maintain its adjusted EBITDA margin at 23.5% through operational execution and financial discipline, despite competitive pressures in the IOL and contact lens markets [4] - Bausch + Lomb anticipates continued outperformance of its daily SiHy lenses in the global market and expects mid-single-digit sales growth for Xiidra as net pricing stabilizes [4] Company Overview - Bausch + Lomb operates in the eye health sector across multiple countries, including the US, Canada, and various international markets, with three main segments: Vision Care, Pharmaceuticals, and Surgical [5]

Core Insights - The company reduced its global headcount by approximately 500 positions year-over-year to create a more efficient organizational structure that supports growth [1] - The dry eye franchise has transitioned from a launch phase to a growth phase, focusing on targeted investments and selling excellence to enhance Miebo and Xiidra performance [1] Financial Performance - The company achieved record Q4 performance with 7% constant currency revenue growth and 27% adjusted EBITDA growth, indicating significant operating leverage from a more fixed cost infrastructure [3] - Margin expansion is attributed to 'Vision 27' initiatives, which improved product mix towards higher-margin offerings and enhanced pricing discipline across all segments [3] - Projected 2026 revenue is between $5.375 billion and $5.475 billion, with expectations that each business segment will grow faster than its respective market [3] - Anticipated adjusted EBITDA growth of approximately 15%, nearly three times the rate of revenue growth, targeting a 19% margin at the midpoint [3] Market Position and Strategy - The company leveraged a diversified 'end-to-end' eye health portfolio to outperform the global contact lens market, achieving 7% growth in China despite broader consumer softness [2] - Successfully navigated the voluntary enVista recall, returning the Implantables business to Q1 2025 levels ahead of schedule through strong surgeon trust and uptake of the Envy and Aspire platforms [2] - The company plans to launch the 'Halo' bioactive contact lens material in 2028 following successful top-line data from the first external clinical study [3] Future Outlook - Seasonality is expected to become more pronounced in 2026, with Q1 projected as the lowest point and Q4 as the highest, driven by the increasing prominence of the prescription dry eye business [3] - Forecasting a step-down in capital expenditures to approximately 5% to 6% of revenue in 2026, supporting a target of over 50% cash flow conversion by 2028 [3]

Financial Data and Key Metrics Changes - The company is focused on achieving financial excellence, particularly improving EBITDA margins to align with or exceed competitors [4][5] - A three-year plan was announced, targeting a revenue growth rate of 5%-7% and a consistent margin improvement of approximately 200 basis points per year [12][56] Business Line Data and Key Metrics Changes - The Vision 27 program aims to enhance operational excellence and gross margins, with thousands of employees involved in various projects [5][7] - The contact lens market is experiencing a slowdown, with growth around 4%, but the company is growing faster than the market [23][24] Market Data and Key Metrics Changes - The company noted a slowdown in the Asian markets, particularly in China, which is affecting overall growth [23][24] - The bifurcation in consumer spending is evident, with lower-end consumers feeling more financial pressure compared to middle and high-income consumers [24] Company Strategy and Development Direction - The company is prioritizing organic growth over M&A, with a focus on enhancing its existing pipeline and improving its balance sheet [15][16] - Innovation is a key focus, with new products like Project Halo aimed at addressing significant consumer issues in the contact lens market [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve its targets, citing recent sales growth and margin improvements as indicators of progress [10][56] - The company is optimistic about the future, expecting to see continued growth and innovation leading to a stronger market position [5][10] Other Important Information - The company is committed to improving its liquidity and addressing its ownership structure, which is currently 88% owned by Bausch Health [11] - The pipeline is projected to generate over $7 billion in potential revenue, highlighting significant growth opportunities [54] Q&A Session Summary Question: What components contributed to the 5%-7% revenue long-range plan? - Management acknowledged the difficulty in predicting future performance but expressed confidence in their balanced guidance based on current market conditions [12][13] Question: How does the company view tuck-in M&A? - The company currently does not require M&A for its three-year plan, focusing instead on organic growth and improving its balance sheet [15][16] Question: What is the expected timeline for new product launches? - The company anticipates launching new products, including a bioactive contact lens, by 2028, with clinical studies ongoing [19][22] Question: How is the company managing its R&D budget? - The company is increasing its R&D budget to approximately 7.5% of revenue, focusing on programs that promise the best returns [36][38] Question: What is the outlook for the dry eye market? - Management believes they have the best portfolio for treating dry eye, with Xiidra and Miebo positioned as leading products in the market [40][41]

Financial Data and Key Metrics Changes - The company is focused on achieving financial excellence, particularly improving EBITDA margins to align with or exceed competitors [5][6][11] - A three-year plan was announced, targeting a revenue growth rate of 5%-7% [13][15] - The company aims for a net leverage of 3.5 times by 2028 [18] Business Line Data and Key Metrics Changes - The Vision 27 program is designed to enhance operational efficiency and gross margins across various business lines [6][11] - The contact lens segment is expected to grow faster than the market, with a new bioactive platform, Project Halo, set to launch in 2028 [21][27] - The dry eye product portfolio, including Xiidra and Miebo, is positioned as the gold standard in the market [52] Market Data and Key Metrics Changes - The contact lens market has slowed to about 4% growth, influenced by economic conditions in Asia, particularly China [28][29] - The company anticipates a recovery in the contact lens market, projecting growth to return to 5% or higher by 2026 [29] Company Strategy and Development Direction - The company is committed to organic growth, with no M&A planned in the three-year strategy [18] - Focus on innovation is critical, with a deep pipeline of products expected to drive future growth [90] - The company aims to leverage its existing infrastructure for new product launches to maintain high margins [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation into a high-performance competitor, emphasizing the importance of innovation and operational excellence [5][6] - The management highlighted the need for a disciplined approach to spending as growth resumes [9][11] - The company is optimistic about the aging population's demand for premium IOLs, viewing it as a growth driver [89] Other Important Information - The company is focusing on enhancing its R&D efficiency, aiming to allocate more resources towards product development rather than administrative costs [50] - The introduction of new products like Lumify Luxe and the expansion of the PreserVision brand are seen as significant growth opportunities [44][46] Q&A Session Summary Question: How should investors think about the liquidity of Bausch + Lomb given its ownership structure? - Management acknowledged the 88% ownership by Bausch Health and indicated that both boards are committed to addressing liquidity issues, though the timeline is uncertain [12] Question: What are the components of the 5%-7% revenue long-range plan? - Management explained that the guidance is based on current market conditions and internal capabilities, with a balanced approach to growth [13][15] Question: How does the company view tuck-in M&A opportunities? - Management stated that no M&A is needed at this time, focusing instead on organic growth and improving the balance sheet [18] Question: What is the expected timeline for the new bioactive contact lens material? - The new product is expected to launch in 2028, with ongoing clinical studies providing positive data [24][27] Question: How does the company plan to manage its R&D budget? - The company is increasing its R&D spending to about 7.5% of revenue, focusing on high-potential programs [48][50] Question: What is the outlook for the dry eye market? - Management believes they have the best portfolio for dry eye treatment, with Xiidra and Miebo positioned as leading products [52] Question: What is the growth outlook for the surgical business? - The surgical business is expected to grow steadily, driven by an aging population and consistent demand for IOLs [89]